To evaluate the efficacy and safety of adebrelimab combined with chemoradiotherapy in the treatment of esophageal small cell carcinoma
1. Sign a written informed consent to join the study voluntarily;
2. Histologically or cytologically confirmed patients with small cell carcinoma of the esophagus staging T1N0M0 but unable to tolerate surgery or refusing surgery and patients staging T2-4N0-3M0 [according to AJCC 8th edition TNM criteria];
3. Age 18-75 years old, male or female;
4. ECOG PS 0-1;
1. Esophageal perforation or hematemesis;
2. Uncontrolled pleural effusion, pericardial effusion or ascites requiring repeated drainage;
3. Uncontrolled hypercalcemia or symptomatic hypercalcemia;
4. Other malignancies diagnosed within 5 years prior to the first use of the investigational drug, except malignancies with a low risk of metastasis or death (5-year survival > 90%), such as adequately treated skin basal cell carcinoma or squamous cell skin cancer or cervical carcinoma in situ, may be considered for inclusion;